Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

June 9, 2015June 9, 2015

Vertex and Parion Sciences Join Efforts to Develop Epithelial Sodium Channel (ENaC) Inhibitors for Cystic Fibrosis and Other Pulmonary Diseases

News

Vertex Pharmaceuticals Incorporated and Parion Sciences will begin co-development of experimental epithelial sodium channel (ENaC) inhibitors as a therapy for treating cystic fibrosis (CF) and other pulmonary diseases such as Non-CF Bronchiectasis. The collaborative effort will provide ... Read more

April 7, 2015May 13, 2015

Novel Combination of Antibiotics and Muco-active Agents Act As Efficient Therapy For Bronchiectasis, Antibiotic-resistant Respiratory Diseases

News

A new formulation of drugs was developed to efficiently fight bacteria in the lungs that originate the most frequent respiratory system infections or bacteria-associated pulmonary diseases such as pneumonia, bronchiectasis ... Read more

March 31, 2015March 31, 2015

Prolonged Use of Macrolides Improved Non-CF Bronchiectasis Patients’ Quality of Life in Study

News

A new study entitled “Effects of long-term use of macrocodes in patients with non-cystic fibrosis bronchiectasis: a meta- analysis of randomized controlled trials” was published in the BMC Infectious Diseases ... Read more

March 13, 2015March 13, 2015

Novel Testing Approach For Cystic Fibrosis, non-Cystic Fibrosis Bronchiectasis Sheds Light on Temperate Bacteriophage Populations

News

A recent study identified mixed viral populations in Pseudomonas aeruginosa (Pa) bacteria colonizing the lungs of patients with Cystic Fibrosis and non-Cystic Fibrosis bronchiectasis that may contribute to bacterial pathogenicity in the ... Read more